Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Authors
Keywords
-
Journal
NEURO-ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2022-04-28
DOI
10.1093/neuonc/noac116
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions
- (2020) Patrick Y Wen et al. NEURO-ONCOLOGY
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
- (2020) David A. Reardon et al. JAMA Oncology
- Temozolomide-induced aplastic anaemia: Case report and review of the literature
- (2020) Peter J Gilbar et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
- (2020) Michael Weller et al. Nature Reviews Clinical Oncology
- Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
- (2019) Junfei Zhao et al. NATURE MEDICINE
- Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
- (2019) Timothy F. Cloughesy et al. NATURE MEDICINE
- Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
- (2019) Kurt A. Schalper et al. NATURE MEDICINE
- Radiotherapy, Lymphopenia, and Host Immune Capacity in Glioblastoma: A Potentially Actionable Toxicity Associated With Reduced Efficacy of Radiotherapy
- (2019) Lawrence Kleinberg et al. NEUROSURGERY
- CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015
- (2018) Quinn T Ostrom et al. NEURO-ONCOLOGY
- MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives
- (2017) Domenico Aquino et al. Journal of Immunology Research
- Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
- (2016) D. Mathios et al. Science Translational Medicine
- Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
- (2015) Hideho Okada et al. LANCET ONCOLOGY
- PD-L1 expression and prognostic impact in glioblastoma
- (2015) Edjah K. Nduom et al. NEURO-ONCOLOGY
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
- (2014) Roger Stupp et al. LANCET ONCOLOGY
- Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence
- (2014) A. Radbruch et al. NEURO-ONCOLOGY
- Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
- (2014) C. Tang et al. Cancer Immunology Research
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
- (2013) Jing Zeng et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
- (2013) Mark R. Gilbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy
- (2012) Sadhak Sengupta et al. Clinical & Developmental Immunology
- Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
- (2012) Annika Malmström et al. LANCET ONCOLOGY
- Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
- (2012) Wolfgang Wick et al. LANCET ONCOLOGY
- Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide
- (2011) Stuart A. Grossman et al. CLINICAL CANCER RESEARCH
- Addition of Bevacizumab to Standard Radiation Therapy and Daily Temozolomide Is Associated With Minimal Toxicity in Newly Diagnosed Glioblastoma Multiforme
- (2010) James J. Vredenburgh et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
- (2009) Michael Weller et al. Nature Reviews Neurology
- MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients
- (2008) Alba A. Brandes et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
- (2008) Dieta Brandsma et al. LANCET ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started